ClinicalTrials.gg
CompletedNCT03416270ERADICATE-HFUpdated May 6, 2025Results posted

ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure

A Phase 2 interventional study of Ertugliflozin and Placebo in Type 2 Diabetes Mellitus and Heart Failure, sponsored by University Health Network, Toronto. Completed at 3 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
21st of 28
34 · median 83
Started
2018
with 1 other
Phase 2
3 of 28
none open now
Registered
18th of 28
by date
Lead sponsor
1 of 28
University Health Network, Toronto

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 18th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study aims to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with type 2 diabetes and heart failure (T2D-HF).

Read the detailed description

Newer agents called sodium glucose co-transporter-2 inhibitors (SGLT2i) have been developed to improve glycemic control and lower hemoglobin A1c by increasing glycosuria. SGLT2i also reduce blood pressure and albuminuria in T2D - possibly through natriuresis. Importantly, a landmark trial "EMPA-REG OUTCOME" demonstrated that the SGLT2i "empagliflozin" is the first anti- hyperglycemic agent to reduce mortality and HF risk, and also to decrease the risk of progressive diabetic nephropathy. Similar benefits were also recently reported in the CANVAS Program trial with canagliflozin. Despite the benefits observed in these two pivotal trials, the mechanisms responsible for beneficial effects of SGLT2i in patients with T2D with respect to the development and/or worsening of HF are not currently known.

In light of the results of EMPA-REG OUTCOME, the investigators aim to elucidate the mechanisms whereby the SGLT2i "ertugliflozin" modifies cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients with T2D and HF (T2D-HF). The investigators will test the hypothesis that ertugliflozin increases proximal tubular natriuresis, thereby reducing plasma volume, without inducing significant renal vasoconstriction or activation of the sympathetic nervous system (SNS) (see below, Figure 1). The systematic understanding of the effects of SGLT2i in the setting of HF will enable the design of rational physiology based strategies to decrease the burden of HF, which could have major clinical and research implications internationally.

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Heart Failure

Keywords

  • SGLT2 inhibtion
  • Ertugliflozin
  • Type 2 Diabetes
  • Heart Failure
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects diagnosed with T2D ≥12 months prior to ;
  2. ≥30 ml/min/1.73m2;
  3. Age >18 years;
  4. 6.5%-10.5%;
  5. (BMI) 18.5-45.0 kg/m2;
  6. Blood pressure ≤160/110 and ≥90/60 at screening,
  7. Heart failure with (NYHA) class 2-3 symptoms and ≥20%
  8. Stable dose of maximally tolerated ACE inhibitor, angiotensin receptor blocker or renin inhibitor for at least 30 days
  9. Stable diuretic dose for at least 30 days at the time of baseline physiological assessment
  10. BNP levels at baseline ≥100 pg/ml (no atrial fibrillation), ≥200 pg/ml if in atrial fibrillation

Exclusion criteria

Exclusion Criteria:

  1. Type 1 Diabetes;
  2. Leukocyte and/or nitrite positive urinalysis that is untreated;
  3. Severe hypoglycaemia within 2 months prior to screening;
  4. History of brittle diabetes or hypoglycaemia unawareness based on investigator judgement;
  5. Unstable coronary artery disease with acute coronary syndrome, percutaneous intervention or bypass surgery within 3 months;
  6. valvular disease;
  7. Congestive heart failure secondary to an infiltrative cardiomyopathic process (for example amyloid) or pericardial constriction;
  8. Uncontrolled systemic hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >110) or systemic hypotension (systolic blood pressure \< 90/60 mmHg);
  9. Bariatric surgery or other surgeries that induce chronic malabsorption;
  10. Anti-obesity drugs or diet regimen and unstable body weight three months prior to screening;
  11. Treatment with systemic ;
  12. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;
  13. Pre-menopausal women who are nursing, pregnant, or of and not practicing an acceptable method of ;
  14. Participation in another trial with an drug within 30 days of ;
  15. Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement;
  16. Liver disease, defined by serum levels of , aspartate transaminase, or alkaline phosphatase >3 x as determined during screening;
  17. Active at the time of screening;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Ertuglifozin Treatment Arm

    Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks

    Drug: Ertugliflozin

  • Placebo comparator
    Placebo Arm

    Placebo Matching Ertugliflozin Tablet for 12 weeks

    Drug: Placebo

Interventions

  • Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks

  • DrugPlacebo

    Placebo once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Fractional Excretion of Lithium (FELi)

    The difference in fractional excretion of lithium (FELi) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before lithium excretion was measured in urine and blood.

    Time frame: Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)

  2. Fractional Excretion of Sodium (FENa)

    The difference in fractional excretion of sodium (FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.

    Time frame: Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)

  3. Change in Absolute Fractional Distal Sodium Reabsorption From Baseline (FELi-FENa)

    The difference in fractional excretion of lithium and fractional excretion of sodium (calculated by the difference between FELi and FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.

    Time frame: Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)

Secondary outcomes

  1. Glomerular Filtration Rate (GFR)

    The difference in iohexol-measured GFR with ertugliflozin vs. placebo. 5ml bolus iohexol (Omnipaque 300mg) was infused intravenously over 2 minutes while participants were supine. Iohexol disappearance curve was used to measure GFR over from 2-4 hours after infusion.

    Time frame: Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 12 weeks

  2. Effective Renal Plasma Flow (ERPF)

    The difference in ERPF with ertugliflozin vs. placebo. Paraaminohippurate (PAH) was intravenously administered to measured ERPF.

    Time frame: Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at 12 weeks

  3. Systolic Blood Pressure (SBP)

    The difference in seated SBP with ertugliflozin vs. placebo

    Time frame: chronic (12 weeks)

  4. Diastolic Blood Pressure (DBP)

    The difference in seated DBP with ertugliflozin vs. placebo

    Time frame: chronic (12 weeks)

  5. Heart Rate (HR)

    The difference in seated HR with ertugliflozin vs. placebo

    Time frame: chronic (12 weeks)

  6. LV Ejection Fraction

    Echocardiography for markers of systolic and diastolic function

    Time frame: chronic (12 weeks)

  7. Carotid-femoral Pulse Wave Velocity

    Arterial Stiffness using SphygmaCor software. Pulse points measured at carotid and femoral arteries.

    Time frame: chronic (12 weeks)

  8. Plasma Volume

    Plasma volume will be measured using a non-radioactive technique (indocyanine green dilution)

    Time frame: chronic (12 weeks)

  9. Extracellular Water

    Extracellular water will be measured non-invasively using bioimpedence spectroscopy

    Time frame: chronic (12 weeks)

  10. Cardiac Output

    Cardiac output will also be measured using non-invasive cardiac monitoring (NICOM)

    Time frame: chronic (12 weeks)

  11. Systemic Vascular Resistance

    Systemic vascular resistance will also be measured using non-invasive cardiac monitoring (NICOM)

    Time frame: chronic (12 weeks)

  12. Blood Angiotensin II

    Neurohormones/biomarkers

    Time frame: chronic (12 weeks)

  13. BNP

    Neurohormones/biomarkers

    Time frame: chronic (12 weeks)

  14. Norepinephrine

    Neurohormones/biomarkers

    Time frame: chronic (12 weeks)

  15. Urinary Adenosine

    Neurohormones/biomarkers

    Time frame: chronic (12 weeks)

07

Results

Posted May 6, 2025
Limitations and caveats
There are limitations to the present analysis. Due to increasing use of SGLT2 inhibition for the clinical indication of HF and challenges posed by the COVID-19 pandemic, we were unable to meet the participant recruitment target for this trial. Therefore, our study was potentially underpowered to detect a difference between ertugliflozin and placebo groups in the primary outcome of FELi.

Participant flow

Participant flow — Overall Study
MilestoneErtuglifozin Treatment ArmPlacebo Arm
Started1717
Completed1716
Not completed01

Outcome measures

PrimaryFractional Excretion of Lithium (FELi)

The difference in fractional excretion of lithium (FELi) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before lithium excretion was measured in urine and blood.

Time frame:
Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)
Reported as:
Mean · percentage of filtered lithium excreted
Fractional Excretion of Lithium (FELi)
percentage of filtered lithium excretedErtuglifozin Treatment ArmPlacebo Arm
Week 10.3 ± 6.9-2.3 ± 16.8
Week 120.8 ± 11.0-4.9 ± 16.6
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.36 (12 weeks)
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.56 (1 week)
SecondaryGlomerular Filtration Rate (GFR)

The difference in iohexol-measured GFR with ertugliflozin vs. placebo. 5ml bolus iohexol (Omnipaque 300mg) was infused intravenously over 2 minutes while participants were supine. Iohexol disappearance curve was used to measure GFR over from 2-4 hours after infusion.

Time frame:
Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 12 weeks
Reported as:
Mean · mL/min/1.73 m2
Glomerular Filtration Rate (GFR)
mL/min/1.73 m2Ertuglifozin Treatment ArmPlacebo Arm
Glomerular Filtration Rate (GFR)48.6 ± 4.050.1 ± 4.2
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.303
SecondaryEffective Renal Plasma Flow (ERPF)

The difference in ERPF with ertugliflozin vs. placebo. Paraaminohippurate (PAH) was intravenously administered to measured ERPF.

Time frame:
Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at 12 weeks
Reported as:
Mean · mL/min/1.73 m2
Effective Renal Plasma Flow (ERPF)
mL/min/1.73 m2Ertuglifozin Treatment ArmPlacebo Arm
Effective Renal Plasma Flow (ERPF)399.1 ± 46.8335.6 ± 41.5
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.438
SecondarySystolic Blood Pressure (SBP)

The difference in seated SBP with ertugliflozin vs. placebo

Time frame:
chronic (12 weeks)
Reported as:
Mean · mmHg
Systolic Blood Pressure (SBP)
mmHgErtuglifozin Treatment ArmPlacebo Arm
Systolic Blood Pressure (SBP)132 ± 5128 ± 5
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.599
SecondaryDiastolic Blood Pressure (DBP)

The difference in seated DBP with ertugliflozin vs. placebo

Time frame:
chronic (12 weeks)
Reported as:
Mean · mmHg
Diastolic Blood Pressure (DBP)
mmHgErtuglifozin Treatment ArmPlacebo Arm
Diastolic Blood Pressure (DBP)77 ± 376 ± 3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.92
SecondaryHeart Rate (HR)

The difference in seated HR with ertugliflozin vs. placebo

Time frame:
chronic (12 weeks)
Reported as:
Mean · bpm
Heart Rate (HR)
bpmErtuglifozin Treatment ArmPlacebo Arm
Heart Rate (HR)74 ± 372 ± 3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.405
SecondaryLV Ejection Fraction

Echocardiography for markers of systolic and diastolic function

Time frame:
chronic (12 weeks)
Reported as:
Mean · percentage of output
LV Ejection Fraction
percentage of outputErtuglifozin Treatment ArmPlacebo Arm
LV Ejection Fraction49.2 ± 4.443.6 ± 5.4
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.536
SecondaryCarotid-femoral Pulse Wave Velocity

Arterial Stiffness using SphygmaCor software. Pulse points measured at carotid and femoral arteries.

Time frame:
chronic (12 weeks)
Reported as:
Mean · m/s
Carotid-femoral Pulse Wave Velocity
m/sErtuglifozin Treatment ArmPlacebo Arm
Carotid-femoral Pulse Wave Velocity11.50 ± 1.5012.14 ± 1.42
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.443
SecondaryPlasma Volume

Plasma volume will be measured using a non-radioactive technique (indocyanine green dilution)

Time frame:
chronic (12 weeks)
Reported as:
Mean · ml
Plasma Volume
mlErtuglifozin Treatment ArmPlacebo Arm
Plasma Volume3470.9 ± 4383158.2 ± 491.9
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.849
SecondaryExtracellular Water

Extracellular water will be measured non-invasively using bioimpedence spectroscopy

Time frame:
chronic (12 weeks)
Reported as:
Mean · L
Extracellular Water
LErtuglifozin Treatment ArmPlacebo Arm
Extracellular Water20.1 ± 0.921.8 ± 1.0
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.013
SecondaryCardiac Output

Cardiac output will also be measured using non-invasive cardiac monitoring (NICOM)

Time frame:
chronic (12 weeks)
Reported as:
Mean · L/min
Cardiac Output
L/minErtuglifozin Treatment ArmPlacebo Arm
Cardiac Output5.8 ± 0.35.8 ± 0.3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.844
SecondarySystemic Vascular Resistance

Systemic vascular resistance will also be measured using non-invasive cardiac monitoring (NICOM)

Time frame:
chronic (12 weeks)
Reported as:
Mean · dynes·s·cm5
Systemic Vascular Resistance
dynes·s·cm5Ertuglifozin Treatment ArmPlacebo Arm
Systemic Vascular Resistance1346.7 ± 99.11437.1 ± 99.9
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.262
SecondaryBlood Angiotensin II

Neurohormones/biomarkers

Time frame:
chronic (12 weeks)
Reported as:
Mean · pg/ml
Blood Angiotensin II
pg/mlErtuglifozin Treatment ArmPlacebo Arm
Blood Angiotensin II89.2 ± 7.186.5 ± 7.3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.802
SecondaryBNP

Neurohormones/biomarkers

Time frame:
chronic (12 weeks)
Reported as:
Mean · pg/ml
BNP
pg/mlErtuglifozin Treatment ArmPlacebo Arm
BNP1311.1 ± 400.5576.6 ± 405.3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.327
SecondaryNorepinephrine

Neurohormones/biomarkers

Time frame:
chronic (12 weeks)
Reported as:
Mean · nM
Norepinephrine
nMErtuglifozin Treatment ArmPlacebo Arm
Norepinephrine2.6 ± 0.32.6 ± 0.3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.618
SecondaryUrinary Adenosine

Neurohormones/biomarkers

Time frame:
chronic (12 weeks)
Reported as:
Mean · mM/μmol Cr
Urinary Adenosine
mM/μmol CrErtuglifozin Treatment ArmPlacebo Arm
Urinary Adenosine0.25 ± 0.050.39 ± 0.05
Statistical analysis
  • Ertuglifozin Treatment Arm · Wilcoxon (Mann-Whitney) · p = 0.946
PrimaryFractional Excretion of Sodium (FENa)

The difference in fractional excretion of sodium (FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.

Time frame:
Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)
Reported as:
Mean · percentage of sodium excretion
Fractional Excretion of Sodium (FENa)
percentage of sodium excretionErtuglifozin Treatment ArmPlacebo Arm
Week 1-0.6 ± 1.90.3 ± 1.7
Week 12-0.6 ± 1.60.1 ± 1.3
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.53 (12 week)
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.89 (1 week)
PrimaryChange in Absolute Fractional Distal Sodium Reabsorption From Baseline (FELi-FENa)

The difference in fractional excretion of lithium and fractional excretion of sodium (calculated by the difference between FELi and FENa) with ertugliflozin vs. placebo. This was measured using exogenous lithium administration 12 hours before sodium excretion was measured in urine and blood.

Time frame:
Change in outcomes was measured acute (1 week minus baseline values) and chronic (12 weeks minus baseline values)
Reported as:
Mean · percentage of total sodium reabsorption
Change in Absolute Fractional Distal Sodium Reabsorption From Baseline (FELi-FENa)
percentage of total sodium reabsorptionErtuglifozin Treatment ArmPlacebo Arm
Week 10.8 ± 7.0-2.6 ± 16.7
Week 121.4 ± 10.6-5 ± 16.1
Statistical analysis
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.26 (12 weeks)
  • Ertuglifozin Treatment Arm vs Placebo Arm · Wilcoxon (Mann-Whitney) · p = 0.56 (1 week)

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertuglifozin Treatment Arm0/17 (0%)3/17 (17.6%)0/17 (0%)
Placebo Arm0/17 (0%)1/17 (5.9%)0/17 (0%)
Most frequent serious events
Most frequent serious events
EventErtuglifozin Treatment ArmPlacebo Arm
Heart failure hospitalizationCardiac disorders1/170/17
EmesisGastrointestinal disorders1/171/17
Myocardial infarctionCardiac disorders1/170/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ertuglifozin Treatment ArmPlacebo ArmTotal
Mean69.8 ± 8.769.4 ± 7.569.6 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Ertuglifozin Treatment ArmPlacebo ArmTotal
Female246
Male151328
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ertuglifozin Treatment ArmPlacebo ArmTotal
Caucasian131225
Black101
Asian123
Other235
Region of Enrollment
Region of Enrollment(participants)Ertuglifozin Treatment ArmPlacebo ArmTotal
Canada8816
Netherlands9918
eGFR
eGFR(mL/min/1.73 m2)Ertuglifozin Treatment ArmPlacebo ArmTotal
Mean63.5 ± 23.366.4 ± 22.465 ± 22.9
08

Study locations

3 sites
  • Toronto General Hospital
    Toronto, Ontario M5G2N2, Canada
  • Vanderbilt University Medical Centre
    Amsterdam, De Boelelaan 1117, Netherlands
  • University Medical Center Groningen
    Groningen, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Apr 2021, 33 months.

Results were first posted in May 2025, 4 years after primary completion.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 33 months is close to that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2018
First posted
Jan 31, 2018
StartActual
Jun 28, 2018
Primary completionActual
Apr 14, 2021
CompletionActual
Apr 14, 2021
Results first posted
May 6, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03416270
Responsible party
David Z.I. Cherney (Associate Professor of Medicine, Clinician Scientist, University Health Network, Toronto) — Principal investigator
First posted
Jan 31, 2018
Start date
Jun 28, 2018
Primary completion
Apr 14, 2021
Completion
Apr 14, 2021
Results posted
May 6, 2025
Last update
May 6, 2025

Study contacts

David ZI Cherney, MD PhD
principal investigator · University Health Network, Toronto General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion